Lapam Capital is a healthcare-focused venture capital firm.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Lapam Capital is a healthcare-focused venture capital firm.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2015 | Quest Genomics | Angel Round | 485.4k |
4/2022 | Pleryon Therapeutics | Seed Round | 0 |
2/2021 | Binhui Biotech | Series C | 0 |
9/2015 | WeHand | Series A | 1.6M |
4/2018 | ImmuneOnco Biopharma | Series A | 0 |
3/2020 | Asieris Pharmaceuticals | Series C | 14.2M |
8/2020 | LP Pharmaceuticals | Series C | 72M |
1/2017 | Connect Biopharmaceuticals | Series A | 20M |
11/2017 | Cygnus Biosciences | Series B | 19.6M |
12/2017 | Asieris Pharmaceuticals | Series B | 15.4M |
11/2019 | Clover Biopharmaceuticals | Series B | 43.2M |
9/2015 | TRACEBoard | Series B | 3.1M |
5/2022 | Immunowake | Series A | 20M |
9/2022 | NeuShen Therapeutics | Seed Round | 20M |
8/2013 | Shenogen Pharma Group | Series C | 20M |
9/2017 | COYOTE | Series C | 4.5M |
7/2022 | BridGene Biosciences | Series B | 0 |
3/2021 | Yingbairui Shengwu | Series A | - |
5/2021 | Kangpu Biopharmaceuticals, Ltd. | Series B | 0 |
8/2019 | Stemirna | Series A | 14.2M |
12/2019 | Remegen | Private Equity Round | - |
10/2021 | Leads Biolabs | Series C | 0 |
8/2021 | Ranok Therapeutics | Series B | 40M |
5/2017 | CANbridge Pharmaceuticals | Series B | 25M |
10/2021 | Chance Pharmaceuticals | Series C | 0 |
7/2022 | BridGene Biosciences | Series B | 0 |
5/2022 | Immunowake | Series A | 0 |
4/2022 | Pleryon Therapeutics | Seed Round | 0 |
10/2021 | Chance Pharmaceuticals | Series C | 0 |
10/2021 | Leads Biolabs | Series C | 0 |
8/2021 | Ranok Therapeutics | Series B | 0 |
5/2021 | Kangpu Biopharmaceuticals, Ltd. | Series B | 0 |
3/2021 | Yingbairui Shengwu | Series A | - |
2/2021 | Binhui Biotech | Series C | 0 |
8/2020 | LP Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|